BLUE LIGHT CYSTOSCOPY (BLC) WITH CYSVIEW®/HEXVIX® DECREASES THE RISK OF PROGRESSION AND RECURRENCE IN BLADDER CANCER

Oslo, Norway, November 28th, 2016 Photocure ASA announced the publication of The Comparative effectiveness of fluorescence cystoscopy versus white light cystoscopy (WLC) for initial diagnosis or surveillance of bladder cancer on clinical outcomes: Systematic review and meta-analysis in the Journal of Urology. This review, which was sponsored by the US Agency for Healthcare Research (AHRQ), concluded that Blue Light Cystoscopy with Cysview®/Hexvix® was associated with decreased risk of progression and recurrence of non-muscle invasive bladder cancer versus White Light Cystoscopy alone.

“We are pleased that this comprehensive and evidence based review provides further support for the use of BLC with Cysview® /Hexvix® in the management of bladder cancer. The risk of disease progression or recurrence is a significant concern for patients with bladder cancer and so the availability of treatment approaches that have been shown to reduce that risk is extremely important,” said Kjetil Hestdal, MD, PhD, President and CEO, Photocure ASA.

The AHRQ through its Evidence-based Practice Centers (EPC’s), sponsors the development of systematic reviews to assist public and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science based information on common, costly medical conditions, and new health care technologies and strategies.

The comparative review can be found at:  Comparative Review – AHRQ-BLCC